HDAC9 and carcinoma: Here we demonstrate that LNCaP and MDA-MB-231 carcinoma cells are more sensitive to T-cell-mediated lysis in vitro after clinically relevant exposure to epigenetic therapy with either the pan-HDAC inhibitor vorinostat (Figure 2) or the class I HDAC inhibitor entinostat (Figure 4).